Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000801 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
A Phase 2 study of HIV Infections and Lymphoma, Non-Hodgkin, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 7
- Study locations
NCT00000801 is a Phase 2 study of HIV Infections and Lymphoma, Non-Hodgkin that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 33 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT00000801, a Phase 2 study of HIV Infections and Lymphoma, Non-Hodgkin, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 7
- Study locations
Study Summary
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population. Combined modality therapy may prove of benefit for patients with AIDS-related primary CNS lymphoma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Cytarabine
- DRUG Filgrastim
- DRUG Doxorubicin hydrochloride
- DRUG Vincristine sulfate
Study Locations (7)
California
- San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco
- San Francisco Gen Hosp - San Francisco
Massachusetts
- Beth Israel Deaconess - West Campus - Boston
- ECOG Data Management Office - Brookline
Colorado
- Univ of Colorado Health Sciences Ctr - Denver
New York
- Mount Sinai Med Ctr - New York
South Carolina
- Julio Arroyo - West Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Est. Completion | 1998-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000801
The ClinicalTrials.gov registry entry for NCT00000801 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00000801 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, Colorado.
Frequently Asked Questions
What is clinical trial NCT00000801 about?
NCT00000801 is a clinical study titled "Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma". To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocy...
What is the current status of trial NCT00000801?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. Estimated completion is 1998-04.
What conditions does trial NCT00000801 study?
This clinical trial studies the following conditions: HIV Infections, Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT00000801?
The interventions under investigation include: Cyclophosphamide (DRUG), Cytarabine (DRUG), Filgrastim (DRUG), Doxorubicin hydrochloride (DRUG), Vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00000801?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000801 being conducted?
This trial has 7 study locations across California, Colorado, Massachusetts, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.